Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Yasuhiro Hisanaga"'
Autor:
Yasuhiro Hisanaga, Toshifumi Tada, Shusuke Kitabatake, Akira Kanamori, Takashi Kumada, Tsuyoki Yama, Makoto Tanikawa, Seiki Kiriyama, Hidenori Toyoda
Publikováno v:
Journal of Gastroenterology and Hepatology. 30:1412-1419
Background and Aim It has been reported that the branched-chain amino acid (BCAA) to tyrosine ratio (BTR) is a useful indicator of liver function and BCAA therapy is associated with a decreased incidence of hepatocellular carcinoma (HCC). However, th
Autor:
Toshifumi, Tada, Takashi, Kumada, Hidenori, Toyoda, Seiki, Kiriyama, Makoto, Tanikawa, Yasuhiro, Hisanaga, Akira, Kanamori, Shusuke, Kitabatake, Tsuyoki, Yama, Junko, Tanaka
Publikováno v:
Journal of gastroenterology and hepatology. 32(3)
Eradication of hepatitis C virus (HCV) with interferon (IFN)-based therapy has been reported to reduce all-cause mortality in patients with chronic HCV infection. However, the impact of HCV eradication on non-liver-related mortality and causes of dea
Autor:
Hidenori Toyoda, Akira Kanamori, Takashi Kumada, Junko Tanaka, Shusuke Kitabatake, Yasuhiro Hisanaga, Makoto Tanikawa, Seiki Kiriyama, Toshifumi Tada, Tsuyoki Yama
Publikováno v:
Journal of gastroenterology. 51(4)
Interferon (IFN)-based therapy has been reported to reduce the liver-related mortality rate in patients with chronic hepatitis C virus (HCV) infection. However, predictors of survival and causes of death, including non-liver-related causes, have not
Autor:
Toshifumi, Tada, Takashi, Kumada, Hidenori, Toyoda, Seiki, Kiriyama, Makoto, Tanikawa, Yasuhiro, Hisanaga, Akira, Kanamori, Shusuke, Kitabatake, Tsuyoki, Yama
Publikováno v:
Journal of gastroenterology and hepatology. 30(9)
It has been reported that the branched-chain amino acid (BCAA) to tyrosine ratio (BTR) is a useful indicator of liver function and BCAA therapy is associated with a decreased incidence of hepatocellular carcinoma (HCC). However, there has not been su
Autor:
Hidenori, Toyoda, Takashi, Kumada, Toshifumi, Tada, Seiki, Kiriyama, Makoto, Tanikawa, Yasuhiro, Hisanaga, Akira, Kanamori, Shusuke, Kitabatake, Takanori, Ito
Publikováno v:
Journal of gastroenterology and hepatology. 30(7)
Hepatocellular carcinoma (HCC) can develop in patients with chronic hepatitis C after they have achieved a sustained virologic response (SVR) to antiviral therapy, that is eradication of hepatitis C virus (HCV). Thus, surveillance for HCC remains nec
Autor:
Makoto Tanikawa, Toshifumi Tada, Hidenori Toyoda, Akira Kanamori, Hiroshi Yoshizawa, Yasuhiro Hisanaga, Takashi Kumada, Junko Tanaka, Seiki Kiriyama
Publikováno v:
Journal of gastroenterology. 46(4)
Increases in tumor markers are sometimes seen in patients with chronic liver disease without hepatocellular carcinoma (HCC). The aim of this study was to determine the relationship between the levels of three tumor markers [alpha-fetoprotein (AFP), L
Autor:
Shusuke Kitabatake, Yasuhiro Sone, Kazuhiko Hayashi, Yasuhiro Hisanaga, Takashi Honda, Junichi Shimizu, Koji Nonogaki, Hidenori Toyoda, Seiki Kiriyama, Teiji Kuzuya, Toshifumi Kasugai, Takashi Kumada, Makoto Tanikawa
Publikováno v:
Cancer. 100(11)
BACKGROUND The authors analyzed changes in the characteristics and survival rate of patients with hepatocellular carcinoma (HCC) in the past 25 years. METHODS Trends in clinical characteristics and survival rate of patients with HCC were evaluated re
Autor:
Teiji Kuzuya, Seiki Kiriyama, Takashi Kumada, Yasuhiro Sone, Yasuhiro Hisanaga, Kazuhiko Hayashi, Takashi Honda, Hidenori Toyoda, Makoto Tanikawa
Publikováno v:
Digestive diseases and sciences. 49(2)
In 504 patients with chronic hepatitis C who underwent liver biopsy, the correlation between serum ALT levels and histologic liver inflammation was investigated, and the effects of age, sex, and degree of histologic liver fibrosis on this correlation
Autor:
Takashi Honda, Hidenori Toyoda, Isao Takeda, Yasuhiro Hisanaga, Kazuhiko Hayashi, Takashi Kumada, Yasuhiro Sone, Seiki Kiriyama, Makoto Tanikawa, Satoshi Nakano, Keiichi Sugiyama
Publikováno v:
Oncology. 61(2)
Objective: We evaluated the effect of dose and duration of treatment with interferon (IFN)-α on the incidence of hepatocellular carcinoma (HCC) after IFN treatment in patients with chronic hepatitis C. Methods: A total of 291 noncirrhotic patients w